Source: Fox News
Summary
Researchers at the Washington University School of Medicine in St. Louis have discovered a blood test that can predict a person’s risk of developing Alzheimer’s disease and estimate when symptoms will begin. The test measures levels of the protein p-tau217, which forms “tangles” in the brain that disrupt communication between nerve cells. The study found that p-tau217 levels rise in a consistent pattern long before memory loss begins, and a model using a patient’s age and protein levels can estimate when symptoms will appear, with a margin of error of three to four years.
Our Reading
This guidance has been heard before.
The advice sounds familiar because it echoes previous studies suggesting that biomarkers can predict Alzheimer’s risk. However, this new study takes it a step further by estimating when symptoms will appear. The researchers’ use of a “biological clock” to predict symptom onset is a compelling concept. The study’s limitations, such as the need for more diverse participants and refinement of the test, are acknowledged. As the researchers continue to refine the test, it will be interesting to see how it compares to other biomarkers and imaging tests.
The fact that the test is not yet accurate enough for clinical use or personal medical decision-making is a familiar caveat in the world of medical research.
As the search for effective treatments and prevention strategies continues, this study offers a glimmer of hope for early detection and intervention.
The concept of a “biological clock” for Alzheimer’s is a reminder that our bodies are constantly changing, and that these changes can be tracked and predicted.
The study’s focus on p-tau217 is a testament to the ongoing quest for biomarkers that can accurately detect and predict disease progression.
Author: Evan Null
